Literature DB >> 26784948

Prevalence, Awareness, Treatment, Control and Risk Factors Associated with Hypertension among Adults in Southern China, 2013.

Li Yang1, Jing Yan1, Xinhua Tang1, Xiaoling Xu1, Wei Yu1, Haibin Wu2.   

Abstract

To investigate the prevalence, awareness, treatment, control of hypertension and their associated factors in southern China. A cross-sectional survey was conducted in 5 cities of urban areas and 5 counties of rural areas in Southern China in 2013, a stratified multistage random sampling method was used to select a representative sample. Recruitment included a total of 19254 participants aged 15 or older. Socio-demographic profiles, examinations were administrated on each subject. Multilevel logistic regression models were used to identify the risk factors of hypertension, awareness, treatment, and control. Overall, the prevalence of hypertension and pre-hypertension are 24.59% and 32.11%, respectively in southern China. Among all the hypertensive patients, 67.43% were aware of their condition, 55.76% took anti-hypertension medication recent two weeks, and 30.79% had their blood pressure controlled. Compared with male, female hypertensive patients had higher rates of hypertension awareness, treatment and control. Age, gender, marital status, living areas, education, BMI, waist circumference, visceral adipose index (VAI), high body fat percentage (BFP) and family hypertension history correlated with the prevalence of hypertension. SBP/DBP increased with VAI and BFP increasing. There is an increasing prevalence of hypertension and high pre-hypertension in the general population in southern China, but levels of awareness, treatment, and control remain relatively low, especially for young and middle-aged population. Innovative strategies including of adopting appropriate anti-hypertensive medication therapy and healthy lifestyles should be taken.

Entities:  

Mesh:

Year:  2016        PMID: 26784948      PMCID: PMC4718602          DOI: 10.1371/journal.pone.0146181

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Introduction

Cardiovascular disease (CVD) is one of the leading causes of death and burden worldwide, hypertension has ranked first as a modifiable risk factor of CVD in China [1]. According to the 2002 National Nutrition and Health Survey (NNHS), the prevalence of hypertension in China among adults 18 years or more was 18.8%, the awareness, treatment and control of hypertension were only 30%, 25% and 6%, respectively [2]. Zhejiang province located in Southern China has a population of approximately 55 million in 2013. The result from NNHS in 2002 showed that the prevalence of hypertension among adults 18 years or more in Zhejiang province was 19.8%, the rates of awareness, treatment and control among hypertensive were 37.13%, 29.61% and 10.15%, respectively [2, 3]. As one of the most rapidly developing provinces, dramatic social and economic changes, including rapid urbanization has occurred in Zhejiang over the past 2 decades. Since the survey in 2002, there were no large-scale surveys on hypertension in Zhejiang province, we hope to ascertain the current status of hypertension in this area [1, 4].

Methods

Ethics statement

Ethics approval was obtained from the Zhejiang Hospital Ethics Review Board and the Fuwai Hospital Ethics Review Board both. Written informed consent was obtained from each participant. The ethics committee approved this procedure.

Sampling

We used stratified multistage random sampling method to select representative samples. On the basis of administrative data, it was divided into urban areas and rural areas. Using the probability proportional to size (PPS) method, 5 cities in urban areas and 5 counties in rural areas were selected. We chose two districts or two townships within each city and county, and three communities or villages within each district and township respectively using the simple random sampling (SRS) method. Finally, a given number of participants from each of the 14 gender/age strata (male/female and aged 15–24, 25–34, 35–44, 45–54, 55–64, 65–74, ≥ 75) were chosen also using the SRS method according to the national demographic composition, from communities or villages using the lists compiled from the local government registers of households[4]. As a result of the complex sample, we also considered the design effect when we estimated the sample size. Assuming a design effect of 2.5 and the prevalence of hypertension among population aged 15 years or more of 17.7%, 19000 participants are needed to ensure that the average lengths of the 95% confidence interval (CI) for the prevalence in the entire population and subpopulation defined by age and gender are less than 0.4% and 1.8%, respectively. According to the design, a total of 28000 participants were randomly selected from 10 urban cities and rural counties and invited to participate in the study.

Measurement

Data collection included a questionnaire interview, physical examinations and biochemical examinations. We used the standardized questionnaire developed by the national coordinating center, Fuwai Hospital (Beijing, China), which was administered by trained general practitioners during a face-to-face individual interview. It included demographic information such as age, education and health behaviors such as history of smoking, alcohol consumption, diet and physical activity. We measured blood pressure (BP) with the OMRON HBP-1300 Professional Portable Blood Pressure Monitor (OMRON, Kyoto, Japan) three times on the right arm supported at heart level after the participant sitting at rest for 5 min, with 30 s between each measurement. The average of the three readings would be used for analysis [5,6]. Height was measured without shoes using a standard right angle device and a fixed measurement tape (to the nearest 0.5 cm), and waist circumference in a standing position using a cloth tape directly on the participant's skin (to the nearest 0.5 cm). Body weight without heavy clothing, as well as body fat, visceral fat, was measured using an OMRON body fat and weight measurement device (V-body HBF-371, OMRON, Kyoto, Japan).

Definition

Hypertension is defined as SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg, or self-reported treatment of hypertension with antihypertensive medication. Pre-hypertension is defined as 120 mmHg ≤ SBP ≤ 139 mmHg and/or 80 mmHg ≤ DBP ≤ 89 mmHg, a BP goal of less than 140/90 mmHg for hypertensive is defined as control of hypertension [7,8]. Awareness of hypertension was defined as self-report of any previous diagnosis of hypertension by a healthcare professional before the study. Treatment of hypertension was defined as self-reported use of a prescription medication for management of hypertension during the previous 2 weeks [7-9]. Overweight is defined as body mass index (BMI) ≥ 24 kg/m2 and < 28 kg/m2, obesity was defined as BMI ≥ 28kg/m2 [10]. VAI is classified as standard, slightly high and high [11]. Fasting plasma glucose (FPG) is classified as impaired fasting glucose with FBG ≥ 6.1 mmol/L and ≤ 6.99 mmol/L, diabetes mellitus (DM) as FBG ≥ 7.0 mmol/L[10]. Serum triglycerides (TG) is high with TG ≥ 2.26 mmol/L, serum total cholesterol (TC) is high with TC ≥ 6.22 mmol/L. Low serum high-density lipoprotein cholesterol (HDL-C) are defined as HDL-C < 1.04 mmol/L[10]. Subjects who smoked one cigarette or more per day for over 6 months were defined as smokers, and alcohol drinkers were assessed by asking subjects whether they had consumed more than once every week in the last 12 months. Subjects who consumed more than 6 grams salt per day for over 6 months were defined as excessive salt users [12]. We assessed salt consumption and fruit intake by using a retrospective method of dietary assessment from the food frequency questionnaire designed by Fuwai Hospital (Beijing).

Statistical analysis

The sampling design including stratification, clustering and sampling weights was taken into account in all estimates and analyses using the specific SAS commands. Epidata 3.0 was used for data entry and validation and SAS 9.2 for data management and analysis. Frequencies (percentages) or means and standard deviations were used to summarize the socio-demographic characteristics, physical measurements and hypertension status of participants. Continuous variables and categorical variables were compared by the Student’s t-test/variance analysis and Chi-square test, respectively. The trends in prevalence of hypertension associated factors across categories were analyzed using Chi-square test. And the strength of associations of socio-demographic associated factors of hypertension, awareness, treatment and control were assessed by Odds-Ratios (OR) estimated in logistic regression models. Crude associations were first assessed using univariate models, then associations were assessed using multivariate models adjusted for the covariates age, gender, region, education, retired status, marital status, BMI and family history of hypertension. Significance level was set at p<0.05 for all hypothesis tests.

Results

A total of 19254 study participants from 28000 eligible participants completed all of the questionnaires, measurement examinations. The sex ratio was similar between responders and nonresponders (P>0.05). However, nonresponders were significantly younger than the responders, probably because of their work habits (35 ± 16 years vs. 46 ± 19 years; P < 0.05).

Prevalence and distribution of hypertension

Table 1 showed the prevalence and distribution of normotension, pre-hypertension and hypertension by demographic and socio-economic status among the adults. The prevalence of hypertension and pre-hypertension were 24.59% and 32.11%, respectively. The prevalence of hypertension increased with age and decreased with education levels. The prevalence of the normotension, the pre-hypertension and hypertension was different among the BMI categories and waist circumference categories (P<0.0001, Table 1). The hypertensive had higher BMI, waist circumference, body fat percentage and visceral adipose index, compared with participants having normotension and pre-hypertension (Table 1).
Table 1

Distribution of hypertension by socio demographic and lifestyle factors among the adults of Southern China in 2013 (n = 19254).

CharacteristicsNormotension (N = 8336)Pre-hypertension (N = 6183)Hypertension (N = 4735)P-value
Prevalence, n (%)8336 (43.3)6183 (32.1)4735 (24.6)<0.0001
Age, 15–39, n (%)5257 (63.5)2679 (32.4)325 (3.9)<0.0001
  40–49, n (%)1483 (44.6)1270 (38.2)571 (17.2)
  50–59, n (%)777 (31.4)846 (34.24)848 (34.3)
  60 and above, n (%)807 (15.6)1383 (26.72)2985 (57.7)
 Mean ± SD36.0 ± 15.744.5 ± 17.963.1 ± 15.0<0.0001
Sex men, n (%)3262 (34.1)3839 (40.1)2480 (25.9)<0.0001
Area of residence, n (%)
  Urban4223 (43.2)3202 (32.8)2352 (24.1)0.0871
  Rural4113 (43.4)2981 (31.5)2383 (25.2)
Education, n (%)
  Illiterate680 (20.6)956 (28.9)1672 (50.5)<0.0001
  Primary1265 (31.1)1258 (31.0)1540 (37.9)
  Middle4945 (53.7)2953 (32.1)1314 (14.3)
  College or higher1445 (54.1)1015 (38.0)209 (7.8)
Family history of hypertension, n (%)2481 (30.3)1975 (32.9)1510 (34.5)<0.0001
Smoker, n (%)1339 (32.4)1660 (40.2)1136 (27.5)<0.0001
Alcohol intake, n (%)1541 (31.0)1857 (37.4)1570 (31.6)<0.0001
Excessive salt, n (%)3363 (42.1)2447 (30.7)2172 (27.2)<0.0001
Adequate physical activity, n (%)6158 (43.5)4481 (31.6)3528 (24.9)0.0081
Fruit intake (g / day), Mean (SD)174.5 ± 170.8164.1 ± 190.2121.0 ± 167.8<0.0001
BMI(kg/m2)
  Underweight (BMI<18.5)1150 (65.8)320 (18.3)277 (15.9)<0.0001
  Normal (18.5≤BMI<24.0)5540 (50.4)3470 (31.6)1973 (18.0)
  Overweight (24≤BMI<28.0)1424 (28.2)1843 (36.5)1785 (35.3)
  Obese (BMI≥28.0)222 (15.1)550 (37.4)700 (47.6)
  Mean ± SD22.2 ± 31.523.9 ± 28.824.7 ± 10.0<0.0001
AWC (cm)
  <90 for M, <85 for F, n (%)7495 (50.2)4683 (31.4)2741 (18.4)<0.0001
  ≥90 for M, ≥85 for F, n (%)502 (23.6)755 (35.5)872 (41.0)
  ≥95 for M, ≥90 for F, n (%)338 (15.3)745 (33.8)1122 (50.9)
 Mean ± SD75.8 ± 26.882.2 ± 21.986.2 ± 28.6<0.0001
Blood pressure (mmHg)
  Systolic109.0 ± 7.3127.1 ± 5.7145.2 ± 23.6<0.0001
  Diastolic66.1 ± 6.675.4 ± 7.281.6 ± 11.7<0.0001
Biochemical measurements (mmol/L)
  FBG5.3 ± 1.25.4 ± 1.15.7 ± 1.4<0.0001
  TG1.2 ± 1.11.7 ± 1.71.7 ± 1.4<0.0001
  TC4.9 ± 0.95.2 ± 1.05.2 ± 1.1<0.0001
  HDL-C1.4 ± 0.31.4 ± 0.41.4 ± 0.3<0.0001
BFP
 <10 for M, <20 for F, n (%)733 (72.2)244 (24.0)38 (3.7)<0.0001
 10–19 for M, 20–29 for F, n (%)4712 (62.1)2159 (28.4)720 (9.5)
 20–24 for M, 30–34 for F, n (%)2041 (35.5)2101 (36.5)1610 (28.0)
 ≥25 for M, ≥35 for F, n (%)753 (16.4)1596 (35.1)2198 (48.5)
  Mean ± SD for M18.8 ± 6.721.9 ± 6.324.8 ± 6.0<0.0001
  Mean ± SD for F26.7 ± 5.429.9 ± 6.234.1 ± 5.2<0.0001
VAI
  1–96748 (51.6)4033 (30.8)2303 (17.6)<0.0001
  10–14716 (19.7)1387 (38.1)1536 (42.2)
  15–30129 (10.1)450 (35.1)703 (54.8)
  Mean ± SD for M6.7 ± 5.49.1 ± 5.011.4 ± 5.6<0.0001
  Mean ± SD for F4.5 ± 4.56.6 ± 4.48.3 ± 4.9<0.0001

BMI: Body mass index. TG: Triglycerides. TC: Total cholesterol. HDL-C: high density lipoprotein cholesterol. AWC: Abdominal waist circumference. FBG: Fasting blood glucose. BFP: Body fat percentage. VAI: Visceral adipose index. M: Male. F: Female.

BMI: Body mass index. TG: Triglycerides. TC: Total cholesterol. HDL-C: high density lipoprotein cholesterol. AWC: Abdominal waist circumference. FBG: Fasting blood glucose. BFP: Body fat percentage. VAI: Visceral adipose index. M: Male. F: Female. Figs 1 and 2 showed the SBP/DBP by sex and areas how it changed with increasing visceral adipose index (VAI) and body fat percentage (BFP), respectively. The regression coefficients (RC) and 95% CI of VAI and SBP among men and women were 1.24 (1.17–1.31) and 2.09 (1.99–2.18), respectively, and the linear trend test showed that there was statistical significance (F = 211.05, P<0.0001), meaning VAI maybe had a more important effect on SBP for women, compared with men (Fig 1a). There were similar results for VAI on DBP (F = 11.42, P = 0.001) between male (RC = 0.69, 95% CI: 0.65–0.74) and female (RC = 0.81, 95% CI: 0.76–0.86) (Fig 1b). We could also find that VAI might have a more important effect on SBP (F = 10.87, P = 0.001) and DBP (F = 11.95, P = 0.001) for rural areas, compared with urban areas (Fig 1c and 1d)). Meanwhile, BFP had a more important effect on SBP (F = 193.97, P<0.0001) for female (RC = 1.39, 95% CI: 1.33–1.45), compared with male (RC = 0.85, 95% CI: 0.80–0.90) (Fig 2a), but there was no statistical difference for BFP on DBP between the two groups (F = 2.03, P = 0.154) (Fig 2c). And BFP might have a more important effect on SBP (F = 18.5, P<0.0001) and DBP (F = 8.62, P = 0.003) for rural areas, compared with urban areas (Fig 2c and 2d).
Fig 1

Mean systolic and diastolic blood pressure by VAI between different gender and areas.

(a) mean SBP by VAI between different genders; (b) mean DBP by VAI between different genders; (c) mean SBP by VAI between different areas; (b) mean DBP by VAI between different areas.

Fig 2

Mean systolic and diastolic blood pressure by BFP between different gender and areas.

(a) mean SBP by BFP between different genders; (b) mean DBP by BFP between different genders; (c) mean SBP by BFP between different areas; (b) mean DBP by BFP between different areas.

Mean systolic and diastolic blood pressure by VAI between different gender and areas.

(a) mean SBP by VAI between different genders; (b) mean DBP by VAI between different genders; (c) mean SBP by VAI between different areas; (b) mean DBP by VAI between different areas.

Mean systolic and diastolic blood pressure by BFP between different gender and areas.

(a) mean SBP by BFP between different genders; (b) mean DBP by BFP between different genders; (c) mean SBP by BFP between different areas; (b) mean DBP by BFP between different areas.

Awareness, treatment and control of hypertension

As showed in Table 2, of the 4735 hypertensive individuals, 3161 (1540 men and 1651 women) were aware of their condition. The awareness rate of hypertension was 67.43%, there was significant difference between men and women (62.15% vs 73.25%, P<0.0001). Subjects living in rural places, retired, single had lower awareness rates. The treatment rate of hypertension was 55.76%, 2640 hypertensive individuals took prescription medication recent two weeks, women had a higher treatment rate than men (62.17% vs 49.92%, P<0.0001). But only 30.79% had their BP under control among hypertensive. There was no significant association between men and women (29.88% vs 31.80%, P>0.05). The rate of controlled hypertension was decreased with BMI, increased with age and the level of education. Smokers, drinkers, and the groups with family history of hypertension, living in rural places, retired, single, high FBG, TG or TC had lower control rate of hypertension (Table 2).
Table 2

Percentage of awareness, treatment and control of hypertension among hypertensives in Southern China in 2013 (N = 4735).

Demographic factorsAwarenessTreatmentControl
N (%)95%CIN (%)95%CIN (%)95%CI
Percentage3191(67.43)66.08–68.772640(55.76)54.33–57.181458(30.79)29.48–32.13
Age groups, y
 15–3966 (20.31)16.07–25.1028(8.62)5.80–12.2119(5.85)3.56–8.98
 40–49311 (54.47)50.28–58.61225(39.40)35.37–43.55142(24.87)21.37–28.63
 50–59573 (67.57)64.30–70.71454(53.54)50.11–56.94280(33.02)29.86–36.30
 60 and above2237(75.02)73.42–76.561930(64.66)62.91–66.371015(34.00)32.30–35.73
Male1540(62.15)60.20–64.061238(49.92)47.93–51.91741(29.88)28.08–31.72
Area of residence
 Urban1650(70.18)68.29–72.031369(58.21)56.18–60.21833(35.42)33.48–37.39
 Rural1541(64.72)62.76–66.641271(53.34)51.31–55.35625(26.23)24.47–28.04
Retired1311(59.92)57.83–61.981052(48.06)45.95–50.18618(28.23)26.35–30.17
Married2565(67.84)66.32–69.332110(55.76)54.18–57.371219(32.22)30.73–33.74
Education level
  Illiterate1196(71.57)69.34–73.73984(58.85)56.45–61.22449(26.85)24.74–29.05
  Primary1075(69.90)67.60–72.19897(58.25)55.74–60.72521(33.83)31.47–36.26
  Middle789(60.05)57.34–62.71641(48.78)46.05–51.52401(30.52)28.04–33.09
  College or higher131(62.68)55.74–69.25118(56.46)49.45–63.2987(41.63)34.87–48.63
 BMI, Normal64.00(1262)61.83–66.1252.71(1040)50.48–54.9331.02(612)28.98–33.11
  Overweight71.30(1272)69.14–73.3959.55(1063)57.23–61.8431.88(569)29.72–34.10
  Obese68.29(478)64.70–71.7255.43(388)51.66–59.1537.43(262)34.15–40.90
AWC,<90 for M, <85 for F, n (%)64.15(1757)62.32–65.9553.01(1453)51.12–54.6930.61(839)28.89–32.37
  ≥90 for M, ≥85 for F, n (%)71.10(620)67.97–74.0958.49(510)55.13–61.7633.26(290)30.13–36.49
  ≥95 for M, ≥90 for F, n (%)72.61(814)69.90–75.2160.34(677)57.41–63.2223.32(329)26.67–32.06
Smoker58.15(660)55.22–61.0444.37(504)41.45–47.3125.44(289)22.93–28.08
Drinker62.56(981)60.11–64.9748.92(768)46.42–51.4227.64(434)25.44–29.93
Adequate physical activity68.34(2409)66.78–69.8756.60(1997)54.95–58.2531.77(1121)30.24–33.34
Salt use (≥6 gram)67.33(1461)65.31–69.3055.29(1201)53.17–57.4030.29(658)28.37–32.26
Diabetes73.71(129)66.54–80.0761.14(107)53.50–68.4129.71(52)23.05–37.08
TG ≥2.26123(59.71)52.67–66.4795(46.12)39.17–53.1839(18.93)13.82–24.96
TC ≥6.22112(66.27)58.61–73.3580(47.34)39.62–55.1532(18.93)13.33–25.67
HDL-C <1.042651(68.43)66.94–69.892245(57.91)56.33–59.471198(30.92)29.59–32.57
FBG,≤63011(67.32)65.92–68.692499(55.83)54.36–57.291388(31.01)29.66–32.39
  6.1–6.9105(71.43)63.40–78.5782(55.78)47.37–63.9644(29.93)22.66–38.03
  ≥775(66.96)57.44–75.5659(52.68)43.02–62.1926(23.21)15.76–32.14
BFP, <10 for M, <20 for F, n (%)24(63.16)45.99–78.1921(55.26)38.30–71.3814(36.84)21.81–54.01
 10–19 for M, 20–29 for F, n (%)410(57.02)53.31–60.66319(44.31)40.64–48.02231(32.09)30.14–34.10
 20–24 for M, 30–34 for F, n (%)1021(63.42)61.01–65.77841(52.24)49.76–54.70477(29.63)27.40–31.92
 ≥25 for M, ≥35 for F, n (%)1601(73.54)71.63–75.361344(61.71)59.49–63.60663(30.42)27.07–33.92
VAI, 1–91496(64.99)63.00–66.941240(53.84)51.78–55.89725(31.48)29.59–33.42
  10–141047(68.16)65.77–70.49857(55.79)53.27–58.30471(30.66)28.36–33.04
  15–30524(74.64)71.25–77.82437(62.16)58.46–65.76215(30.58)27.19–34.14

BMI: Body mass index. TG: Triglycerides. TC: Total cholesterol. HDL-C: high density lipoprotein cholesterol. FBG: Fasting blood glucose. BFP: Body fat percentage. VAI: Visceral adipose index. M: Male. F: Female. AWC: Abdominal waist circumference.

BMI: Body mass index. TG: Triglycerides. TC: Total cholesterol. HDL-C: high density lipoprotein cholesterol. FBG: Fasting blood glucose. BFP: Body fat percentage. VAI: Visceral adipose index. M: Male. F: Female. AWC: Abdominal waist circumference.

Antihypertensive medications among treated patients

Fig 3 provided a classification of the prescriptions by type antihypertensive medication among the patients with antihypertensive medications therapy. 55.76% patients with hypertension were prescribed an antihypertensive medication, the most prescribed were calcium channel blockers. Urban participants, compared with rural participants, more frequently used a combination of antihypertensive drugs, most were single pill combination treatment (P<0.001, Fig 3).
Fig 3

Distribution of antihypertensive medications prescribed.

ACEI = angiotensin—converting enzyme inhibitors, ARB = angiotensin—receptor blocker, CCB = calcium—channel blocker.

Distribution of antihypertensive medications prescribed.

ACEI = angiotensin—converting enzyme inhibitors, ARB = angiotensin—receptor blocker, CCB = calcium—channel blocker.

Factors associated with hypertension on prevalence, awareness, treatment and control

Logistic regression models including crude model and adjusted model were used to assess factors associated with hypertension on prevalence, awareness, treatment and control, respectively. The model adjusted for demographic factors such as gender, region, age, education level, retired status, marital status, BMI, family history of hypertension, showed that elderly, male, retired, single, living in rural areas compared with living in urban areas, low level of education, family history of hypertension, alcohol use, overweight, obesity, central obesity, visceral adipose, high body fat percentage and high FPG were associated with hypertension (Table 3).
Table 3

Factors associated with hypertension prevalence among adults and awareness, treatment and control among hypertensive in southern China in 2013.

Variableshypertension prevalenceHypertension awarenessHypertension treatmentHypertension control
Crude OR (95% CI)Adjusted OR*(95% CI)Crude OR (95% CI)Adjusted OR*(95% CI)Crude OR (95% CI)Adjusted OR*(95% CI)Crude OR (95% CI)Adjusted OR*(95% CI)
Age (ref: 15–39 years)
40–495.0 (4.3–5.7)4.0 (3.4–4.7)4.5 (3.3–6.1)4.3 (3.1–6.0)6.3(4.2–9.5)5.8 (3.9–8.8)4.9 (3.0–7.9)5.6 (3.4–9.3)
50–5912.6 (10.9–14.4)10.5 (8.9–12.4)7.8 (5.8–10.5)7.8 (5.7–10.8)11.2 (7.5–16.5)10.6(7.1–15.8)7.3 (4.6–11.6)10.2 (6.3–10.7)
60 and above32.8 (29.0–37.0)32.4 (27.5–38.2)11.2 (8.5–14.8)11.5 (8.4–15.7)17.7 (12.1–25.8)18.1 (12.2–26.7)7.6 (4.9–11.9)13.4 (8.3–21.7)
Gender(ref: Female)1.2 (1.1–1.2)1.4 (1.3–1.6)0.6 (0.5–0.7)0.7 (0.6–0.8)0.6 (0.5–0.7)0.7 (0.7–0.8)0.9 (0.8–1.0)0.8 (0.7–0.9)
Retired(ref: No)3.9 (3.6–4.2)1.2 (1.1–1.4)1.9 (1.7–2.1)1.2 (1.0–1.4)1.8 (1.6–2.0)1.1 (0.9–1.2)1.3 (1.1–1.4)1.0 (0.9–1.2)
Region(ref: Urban)1.1 (1.0–1.1)1.1 (1.0–1.2)0.8 (0.7–0.9)0.8 (0.7–0.9)0.8 (0.7–0.9)0.8 (0.7–0.9)0.7 (0.6–0.7)0.7 (0.6–0.8)
Marital (ref: Married)0.6 (0.6–0.7)1.3 (1.2–1.5)0.9 (0.8–1.1)0.8 (0.7–0.9)1.0 (0.9–1.2)0.9 (0.7–1.0)0.7 (0.6–0.8)0.8 (0.7–1.0)
Education level (ref: College or higher)
Middle2.0 (1.7–2.3)1.1 (0.9–1.4)0.9 (0.7–1.2)1.7 (1.5–2.0)0.7(0.6–0.9)1.5 (1.4–1.8)0.6 (0.5–0.9)0.5 (0.4–0.7)
Primary7.2 (6.2–8.4)1.2 (1.0–1.5)1.4 (1.0–1.9)1.6 (1.4–1.9)1.1 (0.8–1.4)1.4 (1.3–1.6)0.7 (0.5–0.9)0.5 (0.3–0.6)
Illiterate1.2 (1.0–1.4)1.4 (1.2–1.8)1.5 (1.1–2.0)1.5 (1.4–1.8)1.1 (0.8–1.5)1.3 (1.2–1.5)0.5 (0.4–0.7)0.3 (0.2–0.4)
BMI (ref: Normal)
Overweight2.5 (2.4–2.7)2.4 (2.2–2.6)1.4 (1.2–1.6)1.7 (1.4–1.9)1.3 (1.2–1.5)1.6 (1.4–1.8)1.0 (0.9–1.2)1.1 (0.9–1.2)
Obese4.2 (3.8–4.7)5.7 (4.9–6.5)1.2 (1.0–1.5)1.8 (1.5–2.3)1.1 (0.9–1.3)1.7 (1.4–2.0)0.8 (0.7–1.0)1.0 (0.8–1.2)
AWC(ref:<90M,<85 F)
≥90 for M,≥85 for F3.1 (2.8–3.4)1.7 (1.5–2.0)1.4 (1.2–1.6)1.6 (1.3–1.9)1.3 (1.1–1.5)1.2 (1.0–1.4)1.1 (0.9–1.3)1.2 (1.0–1.5)
≥95 for M,≥90 for F4.6 (4.2–5.1)1.8 (1.5–2.1)1.5 (1.3–1.7)1.6 (1.4–1.9)1.4 (1.2–1.6)1.1 (0.9–1.4)0.9 (0.8–1.1)1.0 (0.8–1.2)
FHH (ref: No)1.2 (1.1–1.2)2.0 (1.8–2.2)1.3 (1.1–1.5)2.4 (2.0–2.8)1.1 (1.0–1.3)2.1 (1.8–2.5)1.3 (1.1–1.5)1.6 (1.3–1.8)
Smoker (ref: No)1.2 (1.1–1.3)1.0 (0.9–1.1)0.6 (0.5–0.7)0.8 (0.7–0.9)0.6 (0.5–0.6)0.8 (0.6–0.9)0.7 (0.6–0.8)0.7 (0.6–0.9)
Drinker (ref: No)1.6 (1.5–1.7)1.3 (1.1–1.4)0.7 (0.6–0.8)0.9 (0.8–1.1)0.7 (0.6–0.8)0.8 (0.7–0.9)0.8 (0.7–0.9)0.8 (0.6–0.9)
Excessive salt use(ref: <6 gram)1.3 (1.2–1.4)0.9 (0.9–1.0)1.0 (0.9–1.1)0.9 (0.8–1.0)1.0 (0.9–1.1)0.8 (0.7–0.9)1.0 (0.9–1.1)1.0 (0.9–1.1)
Diabetes (ref: No)1.7 (0.9–3.5)1.6 (0.8–3.5)0.8 (0.3–2.6)0.5 (0.1–1.7)1.3 (0.5–3.4)0.8 (0.2–2.4)1.1 (0.4–3.2)0.8 (0.2–2.6)
TG (ref: <2.26)2.5 (2.1–3.0)1.4 (1.2–1.8)0.7 (0.5–0.9)0.7 (0.5–0.9)0.7 (0.5–0.9)0.6 (0.4–0.8)0.5 (0.4–0.7)0.5 (0.4–0.8)
TC (ref: <6.22)2.5 (2.0–3.0)1.1 (0.9–1.4)1.0 (0.7–1.3)0.8 (0.6–1.1)0.7 (0.5–0.9)0.5 (0.4–0.8)0.5 (0.4–0.8)0.5 (0.3–0.8)
FBG (ref: ≤6)
 6.1–6.93.7 (2.9–4.7)1.7 (1.3–2.3)1.2 (0.8–1.8)1.0 (0.7–1.5)1.0 (0.7–1.4)0.8 (0.6–1.1)1.0 (0.7–1.4)0.8 (0.6–1.2)
 ≥74.4 (3.3–5.8)1.9 (1.3–2.6)1.0 (0.7–1.5)0.9 (0.6–1.3)0.9 (0.6–1.3)0.7 (0.5–1.1)0.7 (0.4–1.1)0.7 (0.4–1.1)
VAI(ref: <10)
 10–143.5 (3.2–3.8)1.5 (1.4–1.7)1.2 (1.0–1.3)1.4 (1.2–1.7)1.1 (0.9–1.2)1.1 (0.9–1.3)1.0 (0.9–1.1)1.0 (0.8–1.2)
 15–305.7 (5.1–6.5)2.0 (1.6–2.4)1.6 (1.3–1.9)2.1 (1.7–2.6)1.4 (1.2–1.7)1.4 (1.1–1.9)1.0 (0.8–1.2)1.0 (0.7–1.3)
BFP (ref: <10 for M, <20 for F
10–19 for M,20–29 for F0.6 (0.5–0.7)0.6 (0.5–0.8)0.6 (0.4–0.8)0.6 (0.4–0.8)0.5 (0.4–0.7)0.7 (0.5–0.9)1.1 (0.8–1.6)1.1 (0.8–1.6)
20–24 for M 30–34 for F2.1 (1.8–2.4)1.0 (0.8–1.3)0.7 (0.5–1.0)0.7 (0.5–1.0)0.7 (0.6–0.9)0.8 (0.6–1.1)1.1 (0.8–1.5)0.9 (0.7–1.3)
≥25 for M, ≥35 for F5.0 (4.3–5.8)1.3 (1.0–1.5)1.2 (0.9–1.6)1.1 (0.8–1.5)1.1 (0.8–1.4)0.9 (0.7–1.2)1.2 (0.9–1.7)1.2 (1.0–1.4)

FHH: Family history of hypertension. BMI: Body mass index. TG: Triglycerides. TC: Total cholesterol. HDL-C: high density lipoprotein cholesterol. FBG: Fasting blood glucose. BFP: Body fat percentage. M: Male. F: Female. AWC: Abdominal waist circumference. BMI: Body mass index.

*Adjusted for gender, region, age, education level, retired status, marital status, BMI, Family history of hypertension.

FHH: Family history of hypertension. BMI: Body mass index. TG: Triglycerides. TC: Total cholesterol. HDL-C: high density lipoprotein cholesterol. FBG: Fasting blood glucose. BFP: Body fat percentage. M: Male. F: Female. AWC: Abdominal waist circumference. BMI: Body mass index. *Adjusted for gender, region, age, education level, retired status, marital status, BMI, Family history of hypertension. It showed that among those with hypertension, elderly, female, retired, living in urban, married, level of education, overweight, obesity, central obesity, family history of hypertension, nonsmoking, visceral adipose were associated with hypertension awareness (Table 3). In the adjusted model, among those with hypertension, elderly, female, living in urban places, level of education, overweight, obesity, family history of hypertension, nonsmoking, nondrinking, low salt taken, low TG, TC and high visceral adipose index were associated with hypertension treatment (Table 3). Meanwhile, elderly, female, living in urban areas, high level of education, family history of hypertension, nonsmoking, nondrinking, low TC, low TG and high body fat percentage affecting control of hypertension (Table 3).

Discussion

Hypertension has been identified as one of the leading risk factors for global burden of disease and the main risk factor for mortality [13-15]. The prevalence of hypertension among the adult population globally is predicted to increase from 26% in 2000 to 29% by the year of 2025 [16,17]. According to our survey, the prevalence of hypertension in Zhejiang province is 24.56%, increasing more than 19.5%, compared with the prevalence of 19.8% in 2002 [2]. It is lower than those in northern parts of China and higher than developed countries such as United States [18-20]. The prevalence of pre-hypertension is 32.11%, with the most prevalent subgroup of 40–49 which is also the most important workforce group that means more than one third of Zhejiang adult population would have hypertension or elevating risk of CVD for the next few years, if we don’t take any effective measures [21-23]. Awareness, treatment and control of hypertension among adults in Zhejiang province in 2013 were 67.43%, 55.76% and 30.79% respectively, all increased significantly compared with 2002. The improvement was likely to be due in part of the national campaign of hypertension prevention and control proposed by government, as well, people have paid more attention to their health condition with the rapid development of China’s economy. Although hypertension awareness, treatment and control have markedly improved, there were still gaps compared with those of developed countries [20,24,25]. Control of hypertension was unsatisfactory, especially among young and middle-aged population, which remained only 5.85% and 24.87% for 15–39 and 40–49 years old subgroups respectively, and the awareness, treatment were also relative low for them. That might mainly be caused by the neglect and their busy work lifestyle habits including of more stress, with the rapid urbanization in the past few decades in China, which resulted in uncontrolled hypertension. More effective primary prevention measures should be made for the young and middle-aged population, not just for the elderly, to address the rise in hypertension and pre-hypertension. In our survey, those using a combination of antihypertensive drugs including single pill combination treatment had higher control rate compared with those using mono therapy (60.17% vs 52.94%, P<0.0001). More patients used inappropriate antihypertensive medications in rural areas compared with those in urban areas, probablely due to the lack of qualified physicians in these areas. Gender, age, BMI, high TG, high FPG, living in rural areas, low level of education, and family history of hypertension are traditional associated factors of hypertension [1,3,26-28], our study provide additional support to these hypothesis. Some reports have shown that excessive alcohol use and tobacco consumption are also important causes of hypertension [3,29,30], our results support for the alcohol hypothesis, but not for the latter one. In our study, visceral adipose and high body fat percentage were showed also associated with hypertension, the SBP and DBP gradually increased with VAI and BFP. Our study also showed that VAI might have a more important effect on SBP/DBP for women, compared with men. BFP might also have more important effect on DBP for women. VAI/BFP might have a more important effect on SBP/DBP for rural areas, compared with urban areas. Some studies showed that overweight, obesity or central obesity was significantly associated with hypertension [2,3,31-32], our results further confirmed these studies. It is likely that overweight, obesity and central obesity in southern Chinese adults are major contributing factors of hypertension. Our survey showed hypertension awareness and treatment was higher for female which was observed either in other areas [33-35], and the difference maybe because of the developmental and personality factors [3,36]. The hypertension awareness and treatment increased with age, and patients living in urban places, overweight, obesity, with family history of hypertension and higher VAI had higher awareness and treatment rates. Control of hypertension was higher for female, and patients living in urban places, having higher level of education, having better lifestyles such as nonsmoking or nondrinking had better control of hypertension, which were similar with some other studies [1,31,35]. In our survey, BFP more than 25 for men and 35 for women was associated with uncontrolled hypertension. Our study had several strengths and limitations. The main strength of this study was the large sample size, coverage, representativeness of the region population, which were selected according to the national demographic by gender and age. Moreover, it provided new information about hypertension in the general adult population of Southern China. Despite these strengths, there were several limitations. First, our study was a cross-sectional survey, which was failed to establish cause-and-effect relationship between the observed associations. Second, some confounding variables including dietary habits and family income were not included. In conclusion, our results showed an increasing prevalence of hypertension and high pre-hypertension in the general population in southern China, but levels of awareness, treatment, and control remain relatively low, especially for young and middle-aged population. Faced with the epidemiological transition, we need innovative strategies to control and prevent hypertension, including modifying risk factors such as high weight, inappropriate use of antihypertensive drugs and conducting community-based intervention programs to address this serious problem.

Minimal data set.

(XLS) Click here for additional data file.

Healthy condition questionnaire.

(DOCX) Click here for additional data file.
  34 in total

1.  Blood pressure and the global burden of disease 2000. Part II: estimates of attributable burden.

Authors:  Carlene M M Lawes; Stephen Vander Hoorn; Malcolm R Law; Paul Elliott; Stephen MacMahon; Anthony Rodgers
Journal:  J Hypertens       Date:  2006-03       Impact factor: 4.844

2.  Global burden of hypertension: analysis of worldwide data.

Authors:  Patricia M Kearney; Megan Whelton; Kristi Reynolds; Paul Muntner; Paul K Whelton; Jiang He
Journal:  Lancet       Date:  2005 Jan 15-21       Impact factor: 79.321

3.  Prevalence, awareness, treatment, and control of hypertension among adults in Beijing, China.

Authors:  Li Cai; Aiping Liu; Lei Zhang; Shuping Li; Peiyu Wang
Journal:  Clin Exp Hypertens       Date:  2011-10-03       Impact factor: 1.749

4.  Prevalence and control of hypertension in Bangladesh: a multilevel analysis of a nationwide population-based survey.

Authors:  Md Mizanur Rahman; Stuart Gilmour; Shamima Akter; Sarah K Abe; Eiko Saito; Kenji Shibuya
Journal:  J Hypertens       Date:  2015-03       Impact factor: 4.844

Review 5.  Association of all-cause and cardiovascular mortality with prehypertension: a meta-analysis.

Authors:  Yuli Huang; Liang Su; Xiaoyan Cai; Weiyi Mai; Sheng Wang; Yunzhao Hu; Yanxian Wu; Hongfeng Tang; Dingli Xu
Journal:  Am Heart J       Date:  2013-11-06       Impact factor: 4.749

6.  A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010.

Authors:  Stephen S Lim; Theo Vos; Abraham D Flaxman; Goodarz Danaei; Kenji Shibuya; Heather Adair-Rohani; Markus Amann; H Ross Anderson; Kathryn G Andrews; Martin Aryee; Charles Atkinson; Loraine J Bacchus; Adil N Bahalim; Kalpana Balakrishnan; John Balmes; Suzanne Barker-Collo; Amanda Baxter; Michelle L Bell; Jed D Blore; Fiona Blyth; Carissa Bonner; Guilherme Borges; Rupert Bourne; Michel Boussinesq; Michael Brauer; Peter Brooks; Nigel G Bruce; Bert Brunekreef; Claire Bryan-Hancock; Chiara Bucello; Rachelle Buchbinder; Fiona Bull; Richard T Burnett; Tim E Byers; Bianca Calabria; Jonathan Carapetis; Emily Carnahan; Zoe Chafe; Fiona Charlson; Honglei Chen; Jian Shen Chen; Andrew Tai-Ann Cheng; Jennifer Christine Child; Aaron Cohen; K Ellicott Colson; Benjamin C Cowie; Sarah Darby; Susan Darling; Adrian Davis; Louisa Degenhardt; Frank Dentener; Don C Des Jarlais; Karen Devries; Mukesh Dherani; Eric L Ding; E Ray Dorsey; Tim Driscoll; Karen Edmond; Suad Eltahir Ali; Rebecca E Engell; Patricia J Erwin; Saman Fahimi; Gail Falder; Farshad Farzadfar; Alize Ferrari; Mariel M Finucane; Seth Flaxman; Francis Gerry R Fowkes; Greg Freedman; Michael K Freeman; Emmanuela Gakidou; Santu Ghosh; Edward Giovannucci; Gerhard Gmel; Kathryn Graham; Rebecca Grainger; Bridget Grant; David Gunnell; Hialy R Gutierrez; Wayne Hall; Hans W Hoek; Anthony Hogan; H Dean Hosgood; Damian Hoy; Howard Hu; Bryan J Hubbell; Sally J Hutchings; Sydney E Ibeanusi; Gemma L Jacklyn; Rashmi Jasrasaria; Jost B Jonas; Haidong Kan; John A Kanis; Nicholas Kassebaum; Norito Kawakami; Young-Ho Khang; Shahab Khatibzadeh; Jon-Paul Khoo; Cindy Kok; Francine Laden; Ratilal Lalloo; Qing Lan; Tim Lathlean; Janet L Leasher; James Leigh; Yang Li; John Kent Lin; Steven E Lipshultz; Stephanie London; Rafael Lozano; Yuan Lu; Joelle Mak; Reza Malekzadeh; Leslie Mallinger; Wagner Marcenes; Lyn March; Robin Marks; Randall Martin; Paul McGale; John McGrath; Sumi Mehta; George A Mensah; Tony R Merriman; Renata Micha; Catherine Michaud; Vinod Mishra; Khayriyyah Mohd Hanafiah; Ali A Mokdad; Lidia Morawska; Dariush Mozaffarian; Tasha Murphy; Mohsen Naghavi; Bruce Neal; Paul K Nelson; Joan Miquel Nolla; Rosana Norman; Casey Olives; Saad B Omer; Jessica Orchard; Richard Osborne; Bart Ostro; Andrew Page; Kiran D Pandey; Charles D H Parry; Erin Passmore; Jayadeep Patra; Neil Pearce; Pamela M Pelizzari; Max Petzold; Michael R Phillips; Dan Pope; C Arden Pope; John Powles; Mayuree Rao; Homie Razavi; Eva A Rehfuess; Jürgen T Rehm; Beate Ritz; Frederick P Rivara; Thomas Roberts; Carolyn Robinson; Jose A Rodriguez-Portales; Isabelle Romieu; Robin Room; Lisa C Rosenfeld; Ananya Roy; Lesley Rushton; Joshua A Salomon; Uchechukwu Sampson; Lidia Sanchez-Riera; Ella Sanman; Amir Sapkota; Soraya Seedat; Peilin Shi; Kevin Shield; Rupak Shivakoti; Gitanjali M Singh; David A Sleet; Emma Smith; Kirk R Smith; Nicolas J C Stapelberg; Kyle Steenland; Heidi Stöckl; Lars Jacob Stovner; Kurt Straif; Lahn Straney; George D Thurston; Jimmy H Tran; Rita Van Dingenen; Aaron van Donkelaar; J Lennert Veerman; Lakshmi Vijayakumar; Robert Weintraub; Myrna M Weissman; Richard A White; Harvey Whiteford; Steven T Wiersma; James D Wilkinson; Hywel C Williams; Warwick Williams; Nicholas Wilson; Anthony D Woolf; Paul Yip; Jan M Zielinski; Alan D Lopez; Christopher J L Murray; Majid Ezzati; Mohammad A AlMazroa; Ziad A Memish
Journal:  Lancet       Date:  2012-12-15       Impact factor: 79.321

7.  Trends in prevalence, awareness, management, and control of hypertension among United States adults, 1999 to 2010.

Authors:  Fangjian Guo; Di He; Wei Zhang; R Grace Walton
Journal:  J Am Coll Cardiol       Date:  2012-07-11       Impact factor: 24.094

8.  Prevalence and determinants of pre-hypertension and hypertension among the adults in rural Bangladesh: findings from a community-based study.

Authors:  Masuma Akter Khanam; Wietze Lindeboom; Abdur Razzaque; Louis Niessen; Abul Hasnat Milton
Journal:  BMC Public Health       Date:  2015-02-28       Impact factor: 3.295

Review 9.  Visceral adiposity index: an indicator of adipose tissue dysfunction.

Authors:  Marco Calogero Amato; Carla Giordano
Journal:  Int J Endocrinol       Date:  2014-04-14       Impact factor: 3.257

10.  Analysis on associated factors of uncontrolled hypertension among elderly hypertensive patients in Southern China: a community-based, cross-sectional survey.

Authors:  Li Yang; Xiaoling Xu; Jing Yan; Wei Yu; Xinhua Tang; Haibin Wu; Christy L Parkin
Journal:  BMC Public Health       Date:  2014-09-02       Impact factor: 3.295

View more
  37 in total

1.  Hypertension prevalence, awareness, treatment, and control in northeast China: a population-based cross-sectional survey.

Authors:  Fu-Liang Zhang; Zhen-Ni Guo; Ying-Qi Xing; Yan-Hua Wu; Hao-Yuan Liu; Yi Yang
Journal:  J Hum Hypertens       Date:  2017-11-27       Impact factor: 3.012

2.  Awareness of hypertension and related factors in northeastern China: a cross-sectional study.

Authors:  Tianyi Li; Xianjing Song; Junduo Wu; Zhibo Li; Longbo Li; Yunpeng Yu; George A Wells; Bin Liu
Journal:  J Hum Hypertens       Date:  2019-09-23       Impact factor: 3.012

3.  Medical expenditure and its influencing factors of patients with hypertension in Shanxi Province, China: a study based on 'System of Health Accounts 2011' and multiple-layer perceptron neural network.

Authors:  Guojie Liu; Quan Fang; Xinyu Ji; Jing OuYang; Yalan Zhu; Leying Wang; Xin Wang
Journal:  BMJ Open       Date:  2022-03-03       Impact factor: 2.692

4.  Factors associated with stroke among patients with type 2 diabetes mellitus in China: a propensity score matched study.

Authors:  Chenlu He; Wei Wang; Qian Chen; Ziyuan Shen; Enchun Pan; Zhongming Sun; Peian Lou; Xunbao Zhang
Journal:  Acta Diabetol       Date:  2021-06-14       Impact factor: 4.280

5.  Fat-restricted low-glycemic index diet controls weight and improves blood lipid profile: A pilot study among overweight and obese adults in Southwest China.

Authors:  Yuping Liu; Ping Sun; Ping Shuai; Qichuan Qiao; Tingxin Li
Journal:  Medicine (Baltimore)       Date:  2021-05-28       Impact factor: 1.817

6.  Screening for Dementia in Older Adults: Comparison of Mini-Mental State Examination, Mini-Cog, Clock Drawing Test and AD8.

Authors:  Li Yang; Jing Yan; Xiaoqing Jin; Yu Jin; Wei Yu; Shanhu Xu; Haibin Wu
Journal:  PLoS One       Date:  2016-12-22       Impact factor: 3.240

7.  Prevalence of overweight, obesity, abdominal obesity and obesity-related risk factors in southern China.

Authors:  Lihua Hu; Xiao Huang; Chunjiao You; Juxiang Li; Kui Hong; Ping Li; Yanqing Wu; Qinhua Wu; Zengwu Wang; Runlin Gao; Huihui Bao; Xiaoshu Cheng
Journal:  PLoS One       Date:  2017-09-14       Impact factor: 3.240

8.  Prevalence and risk factors associated with hypertension and prehypertension in a working population at high altitude in China: a cross-sectional study.

Authors:  Yang Shen; Chun Chang; Jingru Zhang; Ying Jiang; Bingying Ni; Yanling Wang
Journal:  Environ Health Prev Med       Date:  2017-04-04       Impact factor: 3.674

9.  Sex differences in non-communicable disease prevalence in China: a cross-sectional analysis of the China Health and Retirement Longitudinal Study in 2011.

Authors:  Yan Liu; Guofeng Liu; Hongjiang Wu; Weiyan Jian; Sarah H Wild; Danijela Gasevic
Journal:  BMJ Open       Date:  2017-12-14       Impact factor: 2.692

10.  Psychological, interpersonal, and clinical factors predicting time spent on physical activity among Mexican patients with hypertension.

Authors:  José Luis Ybarra Sagarduy; Dacia Yurima Camacho Mata; José Moral de la Rubia; Julio Alfonso Piña López; José Luis Masud Yunes Zárraga
Journal:  Patient Prefer Adherence       Date:  2018-01-04       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.